Rockwell Med (RMTI) AI Stock Analysis

• Market Cap: $39.25M
• Dividend Yield: N/A
• Average Volume (3M): 1.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.89
• Revenue Growth: -6.79%
• EPS Growth: 61.56%
• Country: US
• Employees: 244
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.05
• Shares Outstanding: 34,430,350
• 10 Day Avg. Volume: 533,052
• 30 Day Avg. Volume: 1,015,804
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: 0.28
• Enterprise Value/Gross Profit: 1.60
• Enterprise Value/Ebitda: 20.02
• 1Y Price Target: $4.00
• Price Target Upside: 247.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 46 Neutral
• Price Target: $1.00 ▼(-13.04% Downside)

Rockwell Med's overall stock score reflects its current financial challenges, particularly in profitability and revenue decline, as well as a challenging valuation. While there are positive signs in cash flow management and strategic initiatives, these are overshadowed by the significant loss of a major customer and ongoing financial difficulties. Technical indicators also suggest caution, contributing to the overall lower score.

Positive Factors

Cash Flow Management

Improved cash flow management enhances financial stability and provides resources for strategic investments, supporting long-term growth.

Long-Term Contracts

Securing long-term contracts increases revenue predictability and customer retention, strengthening the business model against market volatility.

Operational Efficiency

Enhanced operational efficiency through equipment investments helps maintain margins, supporting profitability and competitive positioning.

Negative Factors

Revenue Decline

A significant revenue decline indicates challenges in maintaining market share and customer base, impacting long-term growth potential.

Decreased Profitability

Decreased profitability reflects ongoing cost management issues, which can hinder investment in growth initiatives and competitive edge.

Loss of Major Customer

Losing a major customer poses a risk to revenue stability and highlights potential weaknesses in customer diversification and retention strategies.

Rockwell Med Business Overview & Revenue Model

Company Description

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

How the Company Makes Money

Rockwell Medical generates revenue through the sale of its proprietary medical products, particularly its dialysis solutions and iron therapies. The company markets these products to hospitals, clinics, and dialysis centers, primarily in the United States. Key revenue streams include direct sales of its products and potential licensing agreements with other healthcare firms. Additionally, Rockwell may benefit from partnerships with healthcare providers and institutions that facilitate the adoption of its therapies, contributing to sustained revenue growth.

Rockwell Med Financial Statement Overview

Summary

Rockwell Med's financial performance shows mixed results. While there are improvements in cash flow and leverage, profitability remains a challenge with negative net profit margins and declining revenue. The balance sheet indicates moderate leverage, but negative returns on equity persist.

Income Statement

Rockwell Med's income statement shows a mixed performance. The TTM gross profit margin of 17.52% indicates some improvement in cost management compared to previous years. However, the net profit margin remains negative at -2.39%, reflecting ongoing profitability challenges. Revenue has declined by 9.99% in the TTM period, indicating a concerning trend. The EBIT and EBITDA margins are slightly negative, showing operational inefficiencies.

Balance Sheet

The balance sheet reveals moderate leverage with a debt-to-equity ratio of 0.37 in the TTM period, which is an improvement from previous years. However, the return on equity remains negative at -6.79%, indicating that the company is not generating sufficient returns on shareholders' equity. The equity ratio of 57.79% suggests a reasonable level of financial stability.

Cash Flow

Cash flow analysis shows positive trends with a 30.95% growth in free cash flow in the TTM period. The operating cash flow to net income ratio of 0.32 indicates that the company is generating cash from operations, albeit at a low level. The free cash flow to net income ratio of 0.83 suggests that the company is managing its cash flow better than its net income might suggest.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	87.97M	101.49M	83.61M	72.81M	61.93M	62.20M
Gross Profit	15.41M	17.48M	8.70M	4.08M	-2.42M	2.73M
EBITDA	1.23M	2.95M	-4.69M	-16.17M	-27.80M	-26.72M
Net Income	-2.10M	-480.00K	-8.44M	-18.68M	-32.67M	-30.89M
Balance Sheet
Total Assets	52.63M	59.21M	52.17M	46.63M	48.57M	77.75M
Cash, Cash Equivalents and Short-Term Investments	18.42M	21.60M	10.94M	21.49M	22.44M	58.68M
Total Debt	14.01M	13.54M	13.44M	16.36M	28.89M	23.94M
Total Liabilities	22.22M	26.62M	30.88M	32.53M	46.04M	43.58M
Stockholders Equity	30.41M	32.59M	21.29M	14.11M	2.54M	34.17M
Cash Flow
Free Cash Flow	2.68M	3.19M	-9.70M	-17.70M	-34.06M	-30.69M
Operating Cash Flow	3.50M	4.20M	-9.41M	-17.41M	-33.53M	-29.64M
Investing Cash Flow	-6.55M	-4.87M	-3.04M	-2.40M	311.00K	3.21M
Financing Cash Flow	3.67M	7.35M	11.34M	16.15M	-2.18M	63.32M

Rockwell Med Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RMTI, the sentiment is Negative. The current price of 1.15 is below the 20-day moving average (MA) of 1.19, below the 50-day MA of 1.33, and below the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.05 is Neutral, neither overbought nor oversold. The STOCH value of 40.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RMTI.

Rockwell Med Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPIX	53 Neutral	$51.76M	-16.46	-10.79%	―	11.34%	71.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASRT	49 Neutral	$77.95M	-1.81	-38.40%	―	-11.42%	89.01%
RMTI	46 Neutral	$39.25M	―	-8.65%	―	-6.79%	61.56%
SCYX	45 Neutral	$32.70M	-1.83	-37.22%	―	-66.30%	50.52%
KALA	31 Underperform	$5.78M	-0.12	-708.34%	―	―	51.27%

Rockwell Med Corporate Events

Rockwell Med Appoints Heather Hunter as COO

On September 23, 2025, Rockwell Medical appointed Heather Hunter as the Senior Vice President and Chief Operating Officer. Ms. Hunter’s extensive experience in corporate affairs and communications, notably with Venatorx Pharmaceuticals and Safeguard Scientifics, positions her to significantly impact Rockwell Medical’s strategic operations and industry standing. Her employment agreement includes provisions for salary, bonuses, and stock options, reflecting the company’s commitment to aligning executive incentives with long-term growth objectives.

The most recent analyst rating on (RMTI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Rockwell Med stock, see the RMTI Stock Forecast page.

Rockwell Medical Navigates Transition Amid Financial Challenges

Rockwell Medical’s recent earnings call paints a picture of a company in transition, grappling with both setbacks and strategic advancements. While the financial performance has been impacted by the loss of a major customer, the company has made strides in improving its cash reserves, securing long-term contracts, and maintaining operational efficiency. These positive developments indicate a potential for future growth, although the current financial challenges remain a concern.

Rockwell Medical Reports Q2 2025 Financial Results

Rockwell Medical, Inc. is a healthcare company specializing in the development, manufacture, and distribution of hemodialysis products for dialysis providers worldwide. The company is known for its commitment to high-quality products and excellent customer service.